Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Outlook Therapeutics, Inc.OTLK · Entity 608 | Director | October 03, 2019 | October 07, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Outlook Therapeutics, Inc.
Report date October 03, 2019 · Filed October 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2029-10-03 | Direct | 15,000 |
Reported balance
After 2019-10-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-10-03 · Grant · Acquired 15,000 · Balance 15,000 F1: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on the one year anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2029-10-03 | Direct | 48,207 |
Reported balance
After 2019-10-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-10-03 · Grant · Acquired 48,207 · Balance 48,207 F2: The options were granted under the 2015 Plan in lieu of $47,500 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on the one year anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.
F2: The options were granted under the 2015 Plan in lieu of $47,500 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 03, 2019 Filed Oct 7, 2019 22:10 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 48,207 | $0.99 Strike: $1.40 | $47,498.36 |
DisclosureSEC source: 0001209191-19-052711 · doc4.xml · derivative · entry 2 Thomas Joe · CIK 0001716336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,207 Underlying: Common Stock · 48,207 shares Expires 2029-10-03 F2 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $47,500 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 22:10 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001209191-19-052711 · doc4.xml · derivative · entry 1 Thomas Joe · CIK 0001716336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-10-03 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on the one year anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| October 31, 2017 Filed Nov 2, 2017 22:11 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001209191-17-058963 · doc4.xml · derivative · entry 1 Thomas Joe · CIK 0001716336 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-10-31 F1 · derivative.exercise_date: 33.33% of the shares underlying the option shall vest on each of the first, second and third anniversaries of the grant date, such that 100% of the shares underlying the option shall be vested on October 31, 2020, subject to the Reporting Person providing continued service through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.